Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Guanabenz for adolescent hypertension.

P D Walson, A Rath, K Kilbourne

    Pediatric Pharmacology (New York, N.Y.)
    |January 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Thermalization and criticality on an analogue-digital quantum simulator.

    Nature·2025
    Same author

    Counselling sessions for patients in contact isolation due to multi-drug-resistant organisms improve informedness and reduce dissatisfaction.

    The Journal of hospital infection·2024
    Same author

    Photodynamic coatings kill bacteria on near-patient surfaces in intensive care units with low light intensities.

    The Journal of hospital infection·2024
    Same author

    Retrospective genome-oriented analysis reveals low transmission rate of multidrug-resistant Pseudomonas aeruginosa from contaminated toilets at a bone marrow transplant unit.

    The Journal of hospital infection·2024
    Same author

    Whole-genome sequencing reveals two prolonged simultaneous outbreaks involving Pseudomonas aeruginosa high-risk strains ST111 and ST235 with resistance to quaternary ammonium compounds.

    The Journal of hospital infection·2024
    Same author

    Concerning emergence of a new vancomycin-resistant Enterococcus faecium strain ST1299/CT1903/vanA at a tertiary university centre in South Germany.

    The Journal of hospital infection·2023

    Guanabenz effectively lowered blood pressure in hypertensive children aged 12-21 years. This study found the antihypertensive agent safe and well-tolerated, with mild side effects, suggesting its potential for treating childhood hypertension.

    Area of Science:

    • Pediatric Cardiology
    • Pharmacology
    • Hypertension Management

    Background:

    • Guanabenz is a centrally acting antihypertensive agent.
    • It functions via central alpha-adrenergic receptor stimulation.
    • Existing research indicated no significant adverse effects on renal, cardiac, hepatic, or metabolic functions.

    Purpose of the Study:

    • To assess the safety and efficacy of guanabenz in treating pediatric hypertension.
    • To determine an appropriate dosage range for children.
    • To evaluate short-term adverse effects and therapeutic outcomes.

    Main Methods:

    • An open, uncontrolled, 2-month dose-finding trial.
    • Involved 11 male outpatients aged 12 to 21 years with hypertension.
    • Doses ranged from 3 to 12 mg/day (0.07 to 0.17 mg/kg/day) administered twice daily.

    Related Experiment Videos

    Main Results:

    • Significant reduction in mean supine blood pressure (P < 0.05).
    • Mean supine blood pressure decreased from 135/91/81 mmHg to 124/80/66 mmHg.
    • Significant reduction in mean supine pulse rate (10 beats/minute); standing pulse and body weight remained unaffected.

    Conclusions:

    • Guanabenz demonstrated safety and efficacy in treating childhood hypertension.
    • Adverse effects, including headache, dry mouth, and drowsiness, were mild and did not impede treatment.
    • No laboratory or physical examination abnormalities were observed, supporting guanabenz as a viable option.